



FOR IMMEDIATE RELEASE

Contact:

Samina Bari

Ikaria

(908) 238-6372

samina.bari@ikaria.com

IKARIA® NAMES NEW HEAD OF RESEARCH & DEVELOPMENT

Clinton, NJ, June 1, 2010 – Ikaria, Inc. today announced that Douglas Greene, M.D., has been appointed Executive Vice President of Research and Development (R&D). In this role, Dr. Greene will be responsible for drug-development activities, including pre-clinical and clinical research, translational science, regulatory affairs, clinical pharmacology, pharmacovigilance, medical affairs, and project and portfolio management. Dr. Greene succeeds Ralf Roskamp, M.D., who served as Executive Vice President of R&D since 2007.

"We are proud of our product pipeline, which is a testament to Ralf's strategy and vision, and we thank him for developing a promising pipeline of product candidates, including two which are in late-stage development," commented Daniel Tassé, Chairman and CEO of Ikaria. "However, I am delighted that Doug has joined us, and am confident that we will benefit greatly from his knowledge, experience and leadership in driving the further development of our early- and late-stage pipeline, which we believe will help us achieve our vision of becoming a leader in critical care."

Dr. Greene has over 30 years of experience in academia, and 10 years of experience in the pharmaceutical industry. He joins Ikaria from Sanofi-aventis, where he served in various leadership roles since 2003, including Chief Medical Officer of its US business from 2006-2009. Dr. Greene was a member of the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drug Advisory Committee from 1988-1994, and acted as Chairman of the Advisory Committee from 1990-1994.

About Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for

preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

###